DVA vs. LH, DGX, CHE, RCM, CRVL, AMED, AMN, MD, CCRN, and FMS
Should you be buying DaVita stock or one of its competitors? The main competitors of DaVita include Laboratory Co. of America (LH), Quest Diagnostics (DGX), Chemed (CHE), R1 RCM (RCM), CorVel (CRVL), Amedisys (AMED), AMN Healthcare Services (AMN), Pediatrix Medical Group (MD), Cross Country Healthcare (CCRN), and Fresenius Medical Care (FMS).
DaVita (NYSE:DVA) and Laboratory Co. of America (NYSE:LH) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, community ranking, valuation, profitability, dividends and risk.
DaVita presently has a consensus price target of $144.67, suggesting a potential upside of 1.04%. Laboratory Co. of America has a consensus price target of $241.86, suggesting a potential upside of 23.02%. Given Laboratory Co. of America's stronger consensus rating and higher probable upside, analysts clearly believe Laboratory Co. of America is more favorable than DaVita.
90.1% of DaVita shares are owned by institutional investors. Comparatively, 95.9% of Laboratory Co. of America shares are owned by institutional investors. 2.0% of DaVita shares are owned by company insiders. Comparatively, 0.9% of Laboratory Co. of America shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Laboratory Co. of America received 107 more outperform votes than DaVita when rated by MarketBeat users. Likewise, 64.11% of users gave Laboratory Co. of America an outperform vote while only 61.80% of users gave DaVita an outperform vote.
DaVita has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500. Comparatively, Laboratory Co. of America has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500.
DaVita has higher earnings, but lower revenue than Laboratory Co. of America. DaVita is trading at a lower price-to-earnings ratio than Laboratory Co. of America, indicating that it is currently the more affordable of the two stocks.
DaVita has a net margin of 6.61% compared to Laboratory Co. of America's net margin of 3.52%. DaVita's return on equity of 68.52% beat Laboratory Co. of America's return on equity.
In the previous week, Laboratory Co. of America had 4 more articles in the media than DaVita. MarketBeat recorded 10 mentions for Laboratory Co. of America and 6 mentions for DaVita. DaVita's average media sentiment score of 0.98 beat Laboratory Co. of America's score of 0.88 indicating that DaVita is being referred to more favorably in the media.
Summary
Laboratory Co. of America beats DaVita on 12 of the 18 factors compared between the two stocks.
Get DaVita News Delivered to You Automatically
Sign up to receive the latest news and ratings for DVA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
